New Leaf team five years ago and has made significant contributions to the NLV-II portfolio. Jim Niedel MD PhD has worked with the team continuously for over twelve years and will continue to be a senior member of the NLV investment team for NLV-III, but will change his status to Venture Partner with the closing of NLV-III. In this role, Jim will work full-time with NLV during the NLV-III investment period in building and managing the NLV-III portfolio, and he will continue with full oversight and portfolio management responsibilities for NLV-I and NLV-II. With 80+ years of venture investing experience and decades of operating experience in the industries in which they invest, this 6 member senior team (the “Fund Managers”) brings highly relevant and complementary experience to bear on this Fund. This team of partners is further strengthened by a group of additional investment professionals who add highly relevant scientific and life sciences investment experience and have made significant contributions to the NLV-II portfolio. The New Leaf team is distinctive in that its members have played a leadership role in the healthcare venture capital industry over the last two decades. During this time, the Fund Managers have demonstrated the ability to source high quality investments at all stages, including start-ups, follow-on private investments, company restructurings, and structured public investments. The Fund Managers source deals through a range of activities that rely on their deep relationships in academia, industry, and the investment community (private and public), resulting in differentiated and, in many cases, proprietary deal flow. Once initial investments are made, the Fund Managers are focused on building value in technology based healthcare companies by creating strong management teams and then collaborating with them to develop, manage, and execute capital efficient business plans. Through these efforts, the Fund Managers have earned a reputation as valu